BioRestorative up on partnership to help expand lead therapy clinical application

Biorestorative Therapies

13/03/2023 11:52

** Shares of stem cell therapy developer BioRestorative
Therapies Inc  BRTX.O  jump ~15% to $3.47 premarket 
    ** Co says it has signed an agreement with strategic
advisory firm Bruder Consulting & Venture Group to assist BRTX
in seeking FDA approval to expand clinical application of its
experimental therapy, BRTX-100 
    ** BRTX-100 is co's lead clinical candidate and is being
tested in a mid-stage study in chronic lumbar disc disease,
which causes lower back pain  
    ** BRTX shares have fallen ~4% in the past three months 

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))